PharmaShots | Incisive News in 3 Shots

Subscribe Now

RedHill Biopharma

RedHill’s Talicia Receives Patent from the USPTO for the Treatment of H. Pylori Infections

RedHill’s Talicia Receives Patent from the USPTO for the Treatment of H. Pylori Infections

January 25, 2024

RedHill Biopharma’s Talicia Receives Approval in the United Arab Emirates for the Treatment of H. Pylori

RedHill Biopharma’s Talicia Receives Approval in the United Arab Emirates for the Treatment of H. Pylori

August 2, 2023

RedHill Biopharma Reports Results of Opaganib in P-II/III Study for the Treatment of Severe COVID-19

RedHill Biopharma Reports Results of Opaganib in P-II/III Study for the Treatment of Severe COVID-19

February 8, 2022

RedHill Biopharma Reported New Data From a Prespecified Analysis of All Oral Opaganib's P-II/III Study in Severely Ill Hospitalized COVID-19 Patients.

RedHill Biopharma Reported New Data From a Prespecified Analysis of All Oral Opaganib's P-II/III Study in Severely Ill Hospitalize...

January 14, 2022

Insights+: COVID-19 Healthcare News Monthly Updates - November 2020

Insights+: COVID-19 Healthcare News Monthly Updates - November 2020

November 26, 2020

PharmaShots' Key Highlights of Second Quarter 2020

PharmaShots' Key Highlights of Second Quarter 2020

July 7, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us